ATE524487T1 - Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen - Google Patents

Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE524487T1
ATE524487T1 AT08702628T AT08702628T ATE524487T1 AT E524487 T1 ATE524487 T1 AT E524487T1 AT 08702628 T AT08702628 T AT 08702628T AT 08702628 T AT08702628 T AT 08702628T AT E524487 T1 ATE524487 T1 AT E524487T1
Authority
AT
Austria
Prior art keywords
nap
tau
treatment
tau peptide
neurodegenerative diseases
Prior art date
Application number
AT08702628T
Other languages
English (en)
Inventor
Illana Gozes
Maya Maor
Saar Oz
David Dangoor
Inna Divinski
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE524487T1 publication Critical patent/ATE524487T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT08702628T 2007-01-11 2008-01-10 Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen ATE524487T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88450207P 2007-01-11 2007-01-11
US97011007P 2007-09-05 2007-09-05
PCT/IL2008/000047 WO2008084483A1 (en) 2007-01-11 2008-01-10 Novel therapeutics based on tau/microtubule dynamics

Publications (1)

Publication Number Publication Date
ATE524487T1 true ATE524487T1 (de) 2011-09-15

Family

ID=39364033

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08702628T ATE524487T1 (de) 2007-01-11 2008-01-10 Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen

Country Status (4)

Country Link
US (1) US8377875B2 (de)
EP (1) EP2125873B1 (de)
AT (1) ATE524487T1 (de)
WO (1) WO2008084483A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
SG10201703771WA (en) 2011-09-19 2017-06-29 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
EP3268007B1 (de) * 2015-03-13 2022-11-09 Resverlogix Corp. Zusammensetzungen und therapeutische verfahren zur behandlung von komplementassoziierten erkrankungen
US20210147481A1 (en) * 2017-04-21 2021-05-20 Ohio University Peptide-based inhibitors of mark family proteins
WO2019108835A1 (en) 2017-11-29 2019-06-06 The Trustees Of Columbia University In The City Of New York Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy
US11571396B2 (en) 2019-03-23 2023-02-07 Sandra Sermone Ketamine for treatment of ADNP syndrome and sensory processing deficits

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174862B1 (en) 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
US5998368A (en) 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
CA2202496C (en) 1994-10-17 2010-01-05 Douglas E. Brenneman Neurotrophic peptides of activity dependent neurotrophic factor
US6613740B1 (en) 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
WO1998035042A2 (en) 1997-02-07 1998-08-13 Us Gov Health & Human Serv Activity dependent neurotrophic factor iii (adnf iii)
EP0918091A1 (de) 1997-11-21 1999-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Das Gen XLIS und das XLIS Genprodukt Doublecortin und deren Anwendungen
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
AU5550800A (en) * 1999-06-22 2001-01-09 School Of Pharmacy, University Of London, The Diagnosis and treatment of alzheimer's disease
US6649411B2 (en) 1999-07-30 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
EP1206489B1 (de) 1999-08-18 2004-05-06 RAMOT UNIVERSITY, AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Oral wirksame peptide, die zellschädigung und zelltod verhindern
EP1214598B1 (de) * 1999-09-09 2006-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening nach inhibitoren von "gepaarten helikalen filamenten"
US7250551B2 (en) * 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
US7960334B2 (en) 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
EP1516930A1 (de) * 2003-09-16 2005-03-23 Georg-August Universität Göttingen Zelluläres Model der Tauopathien zur "Lead"-Identifikation und zur Entdeckung von Wirkstoffen
GB2417682A (en) 2004-08-18 2006-03-08 Univ East Anglia Histone deacetylse inhibitor for treating connective tissue disorders
WO2006091728A2 (en) 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
EP1885389A4 (de) 2005-03-23 2012-04-04 Univ Ramot Verwendung von adnf-polypeptiden zur behandlung von peripherer neurotoxizität

Also Published As

Publication number Publication date
US8377875B2 (en) 2013-02-19
US20100303785A1 (en) 2010-12-02
WO2008084483A1 (en) 2008-07-17
EP2125873A1 (de) 2009-12-02
EP2125873B1 (de) 2011-09-14

Similar Documents

Publication Publication Date Title
ATE524487T1 (de) Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen
CY1118902T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
HN2012000012A (es) Inhibidores de bace
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
MA33825B1 (fr) Analogue du peptide d'oxyntomoduline
MX2010001936A (es) Neuroproteccion utilizando mimeticos de peptido semejantes a nap y semejantes a sal.
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
LU92202I2 (fr) Aflibercept
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
WO2008051326A3 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
WO2017197253A3 (en) Peptides and methods for treating neurodegenerative disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties